樂觀
$0.72
情境價格
$3.980
-0.734 (-18.44%)收盤時
Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.
Given the current price of $3.98, a significantly low RSI of 7.381 indicates extreme overselling, but the recent 5-day change of -25.05% and a 1-year change of -53.92% suggest that the stock is in a downward trend. The risk of continued losses is high, especially with a negative forward P/E ratio of 0 and a price-to-sales ratio of 63.17, indicating overvaluation compared to sales. Therefore, it is not a good buy right now.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Biotech Stocks Reach 52-Week Highs Following Key Catalysts

Biotech Stocks Surge with Advanced Biomed Leading Gains

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

Healthcare Stocks Surge with Major Gains

Zhengye Biotechnology Shares Surge, Easing Delisting Concerns
Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.
Given the current price of $3.98, a significantly low RSI of 7.381 indicates extreme overselling, but the recent 5-day change of -25.05% and a 1-year change of -53.92% suggest that the stock is in a downward trend. The risk of continued losses is high, especially with a negative forward P/E ratio of 0 and a price-to-sales ratio of 63.17, indicating overvaluation compared to sales. Therefore, it is not a good buy right now.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。